Shenzhen Kaifa Technology
920029
Shanghai Yongli Belting
300230
Guomai Culture & Media
301052
4
WuHan Hvsen Biotechnology
300871
5
CHANGFU CO.,LTD
871396
CN Stock MarketDetailed Quotes
688767 Hangzhou Biotest Biotech
- 39.83
- +0.73+1.87%
Market Closed Mar 28 15:00 CST
4.25BMarket Cap40.73P/E (TTM)
40.05High39.00Low10.66KlotVolume39.00Open39.10Pre Close42.29MTurnover1.00%Turnover Ratio39.87P/E (Static)106.67MShares40.0552wk High1.83P/B4.25BFloat Cap21.5752wk Low46.92Limit Up106.67MShs Float146.02Historical High31.28Limit Down2.69%Amplitude20.95Historical Low1.30Dividend TTM39.66Avg Price4.25KlotAsk3.26%Div YieldTTM100Lot Size5.98KlotBid
Hangzhou Biotest Biotech News
Wu Shujiang from Botao Bio: Focus on differentiated competition in the in vitro diagnostic Industry POCT subdivision, the commercialization of microfluidic testing products has arrived in its inaugural year | Dialogue with technology innovators.
① "Currently, microfluidic detection products have achieved technical breakthroughs, and customer feedback has been relatively positive." Microfluidic detection products will be the company's new generation of rapid diagnostic products handed over to the market. ② The company focuses on overseas markets, with overseas business accounting for 70%, and the North American and Latin American markets are growing rapidly.
Botao Biology (688767.SH): Deepseek has not been deployed yet.
On March 14, Gelonghui reported that Botuo Biomedical (688767.SH) stated on the interaction platform that the company has not yet deployed Deepseek. The company is closely monitoring the development trends of new technologies such as AI and is actively exploring the application and empowerment of AI and other new technologies in its Business and office.
Botuo Biotech: Botuo Biotech 2024 Annual Performance Report Announcement
Botuo Biotech 2024 Annual Results Report Announcement
Botao Biotechnology (688767.SH): Director and senior management personnel Gao Hongmei plans to reduce shareholding by no more than 0.56 million shares.
On February 6, Gelonghui reported that Botou Biotechnology (688767.SH) announced that it recently received a "Shareholding Reduction Plan Notification Letter" from Ms. Gao Hongmei, a Director and senior management personnel. Due to personal funding needs, Ms. Gao Hongmei intends to reduce her shareholding by no more than 560,000 shares through block trading or centralized bidding, which accounts for no more than 0.5250% of the company's total share capital. The reduction period will be within three months starting from 15 trading days after the announcement of this shareholding reduction plan.
Botuo Biotech: Botuo Biotech\'s 2024 annual results forecast
Botuo Biotech 2024 Annual Results Forecast
Botao Biotechnology (688767.SH): Net income is expected to increase by approximately 59.47% in 2024.
On January 23, Gelonghui reported that Botao Biotechnology (688767.SH) announced its annual earnings forecast for 2024. According to preliminary calculations by the finance department, it is expected that the net income attributable to the parent company's owners will be around 170 million yuan in 2024, an increase of approximately 59.47% year-on-year. The net income attributable to the parent company's owners after deducting non-recurring gains and losses is expected to be around 119 million yuan, an increase of approximately 49.83% year-on-year. The company continues to focus on the POCT in-vitro diagnostics sub-industry, effectively grasping customer needs and actively expanding domestic and international markets.
Bohuo Bio (688767.SH) will distribute 5 yuan for every 10 shares in the first three quarters, with the equity registration date on January 9.
Bote Biological (688767.SH) issued an announcement that the company will implement equity distribution for the first three quarters of 2024, with each share...
Net income sharply declined with the contraction of overseas sales, Botai Biology opens up the microfluidic testing field | Earnings conference
①The rapid decline in overseas income dragged down the performance of Botuo Life Sciences, with overall revenue significantly decreasing compared to before the epidemic, and net income attributable to shareholders has decreased year-on-year for multiple years; ② Considering changes in the external environment, Botuo Life Sciences has terminated two major core investment projects, added the Microfluidic Fluorescence Detection Platform project, and ventured into the microfluidic technology field.
Botuo Biotech Report for the Third Quarter of 2024
Botao Biology (688767.SH): Plans to launch an employee stock ownership plan in 2024.
Galaxy Comprehensive News September 25th | Botuo Biotechnology (688767.SH) announced the 2024 employee stock ownership plan, the stocks in this employee stock ownership plan come from the company's repurchase special account to repurchase Botuo Biotechnology A ordinary shares. The target stocks to be held in this employee stock ownership plan will not exceed 2.15 million shares, accounting for approximately 2.02% of the total 106.666667 million shares of the company's capital stock on the date the draft of this employee stock ownership plan was announced. The funds for this employee stock ownership plan come from legitimate employee compensation, self-raised funds, and other methods allowed by laws and regulations. The company does not provide financial assistance or loans to shareholders.
Hangzhou Biotest BiotechLtd's (SHSE:688767) Shareholders May Want To Dig Deeper Than Statutory Profit
Summary of Botuo Biotech\'s 2024 Semi-Annual Report
Botuo Biotech 2024 Semi-Annual Report
Biotrack (688767.SH) released its semi-annual performance, with a net income of 72.18 million yuan, a year-on-year increase of 17.16%.
Biotech (688767.SH) disclosed its 2024 interim report, during the reporting period the company achieved revenue of 2.67...
Botao Biology (688767.SH): The net income in the first half of the year was 72.1751 million yuan, a year-on-year increase of 17.16%.
On August 29, Golonghui announced its semi-annual report for 2024, with operating revenue of 0.267 billion yuan, a year-on-year increase of 25.97%; net income attributable to shareholders of the listed company was 72.1751 million yuan, a year-on-year increase of 17.16%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 70.1048 million yuan, a year-on-year increase of 31.57%; basic earnings per share were 0.69 yuan.
Botu Biological (688767.SH): Cumulative repurchase of 2.02% of shares, the buyback plan has been completed.
On July 24th, Gelonhui announced that the company's share buyback plan has been completed as of the date of this announcement. The company has repurchased a total of 2,150,000 shares through centralized bidding trading, accounting for 2.02% of the company's total share capital. The highest purchase price was 33.48 yuan/share, the lowest was 22.23 yuan/share, and the average purchase price was 26.95 yuan/share. The total amount paid was RMB 57,949,678.66 (excluding stamp duty, transaction fees, and other expenses).
Biotools (688767.SH): spent a total of 56.93 million yuan to repurchase 1.978% of the shares.
On July 1st, Gelunhui reported that Botro Biotechnology (688767.SH) had repurchased a total of 2,109,838 shares of the company through the Shanghai Stock Exchange trading system by means of centralized bidding trading as of June 30, 2024, accounting for 1.9780% of the company's total share capital of 106,666,667 shares. The highest price of the repurchase transaction was 33.48 yuan/share, the lowest price was 22.23 yuan/share, and the total amount of funds paid was RMB 56,930,164.60 (excluding stamp duty, transaction commission and other transaction fees).
Botuo Biotech (688767.SH) will distribute 8 yuan for every 10 shares in 2023. The stock registration date is June 7
Botuo Biotech (688767.SH) announced that the company will implement the 2023 annual equity distribution to all shares...